Drug ID:Drug166
Drug Name:Izencitinib
CID:124090478
DrugBank ID:DB16660
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03750565, , NCT03408470, , NCT04587713, , NCT02818686, , NCT03758443, , NCT03920254
Molecular Formula:C22H26N8
Molecular Weight:402.5 g/mol
Isomeric SMILES:CC1=CC(=NN1)NC2=NC(=C3C=CC=NC3=C2)NC4C[C@H]5CC[C@@H](C4)N5CCC#N
Synonyms:Izencitinib; 2051918-33-1; TD-1473; Izencitinib [INN]; Izencitinib [USAN]; 2ZT81PV5UM; TD1473; JNJ8398; JNJ-8398; 8-Azabicyclo(3.2.1)octane-8-propanenitrile, 3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-, (3-exo)-
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1235 124090478 Izencitinib 2185 PTK2B Homo sapiens (human) None
dt1236 124090478 Izencitinib 3717 JAK2 Homo sapiens (human) Inhibitor
dt1237 124090478 Izencitinib 3718 JAK3 Homo sapiens (human) Inhibitor
dt1238 124090478 Izencitinib 7297 TYK2 Homo sapiens (human) Inhibitor
dt1239 124090478 Izencitinib 2047 EPHB1 Homo sapiens (human) Inhibitor
dt1240 124090478 Izencitinib 2048 EPHB2 Homo sapiens (human) Inhibitor
dt1241 124090478 Izencitinib 2049 EPHB3 Homo sapiens (human) Inhibitor
dt1242 124090478 Izencitinib 3718 JAK3 Homo sapiens (human) Inhibition
dt1243 124090478 Izencitinib 3717 JAK2 Homo sapiens (human) Inhibition

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03750565 Multiple Dose Ethnobridging PK Study in Healthy Subjects PHASE1 COMPLETED Theravance Biopharma Inflammatory Bowel Diseases; IBD DRUG: TD-1473 - Dose A; DRUG: TD-1473 - Dose B; D… Details
NCT03408470 TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects PHASE1 COMPLETED Theravance Biopharma Intestinal Disorders; Bowel Diseases, Inflammatory DRUG: TD-1473 oral capsule; DRUG: [14C]-TD-1473 I… Details
NCT04587713 Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects PHASE1 COMPLETED Theravance Biopharma Intestinal Disorder; Bowel Diseases, Inflammatory DRUG: TD-1473 [Tablet A]; DRUG: TD-1473 [Tablet B] Details
NCT03555617 A Phase 1, Open-Label, 2-Cohort Study to Assess the Single Dose Pharmacokinetics of Two Formulations of TD-1473 and to Assess the Effect of a High-Fat Meal and Itraconazole on the Pharmacokinetics of TD-1473 in Healthy Subjects PHASE1 Not recruiting Theravance Biopharma Inflammatory Bowel Disease Drug: TD-1473;Drug: Itraconazole Details
NCT03758443 Efficacy & Safety of TD-1473 in Ulcerative Colitis PHASE2|PHASE3 TERMINATED Theravance Biopharma Ulcerative Colitis (UC) DRUG: TD-1473 Dose A|DRUG: TD-1473 Dose B|DRUG: T… Details
NCT03920254 TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study PHASE2|PHASE3 TERMINATED Theravance Biopharma Ulcerative Colitis (UC) DRUG: TD-1473 Dose A|DRUG: TD-1473 Dose B|DRUG: T… Details
NCT02818686 TD-1473 for Active Ulcerative Colitis (UC) PHASE1 COMPLETED Theravance Biopharma Ulcerative Colitis, Active Moderate|Ulcerative Co… DRUG: TD-1473|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits System…

PMID: 35134999
Year: 2022
Relationship Type: Treatment Score: 9.5

Izencitinib (TD-1473), an oral, gut-selective pan-Janus kinase (JAK) inhibitor under investigation for treatment of inflammatory bowel diseases, was …

View Details